Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Polymorphisms, their Allele Combinations and IFN-β Treatment Response in Irish Multiple Sclerosis Patients

1 Jul 2009

Abstract excerpt

INTRODUCTION: IFN-beta is widely used as first-line immunomodulatory treatment for multiple sclerosis. Response to treatment is variable (30-50% of patients are nonresponders) and requires a long treatment duration for accurate assessment to be possible. Information about genetic variations that predict responsiveness would allow appropriate treatment selection early after diagnosis, improve patient care, with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Associations and Epidemiology
Share to Multiple Sclerosis Research Studies
Share to Rheumatoid Arthritis Research and Therapies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19604093
DOI: 10.2217/pgs.09.41

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Polymorphisms, their Allele Combinations and IFN-β Treatment Response in Irish Multiple Sclerosis PatientsPMID 19604093Read ↗

Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients.Semantic proximity Read ↗

Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.Semantic proximity Read ↗

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.Semantic proximity Read ↗

Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis.Semantic proximity Read ↗

Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.Semantic proximity Read ↗

IFN-beta pharmacogenomics in multiple sclerosis.Semantic proximity Read ↗

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.Semantic proximity Read ↗

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.Semantic proximity Read ↗

IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.Semantic proximity Read ↗

Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.Semantic proximity Read ↗

Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.Semantic proximity Read ↗

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.